Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glutamine-rich protein 1 (QRICH1)
- Target
- QRICH1
- Molecular classification
- Transcription factor, Intracellular signaling protein, Contains CARD domain (death-fold–superfamily protein-protein interaction module)
01
Overview
Glutamine-rich protein 1 is a transcriptional regulator encoded by the QRICH1 gene, ubiquitously expressed and highly conserved among mammals. Its CARD domain implicates QRICH1 in apoptosis, inflammation, and immune signaling. QRICH1 localizes to the nucleus and is critical for cellular adaptation to ER stress, operating as a key effector in the PERK–eIF2α axis, and regulates unfolded protein response through transcriptional programs governing proteostasis and cell fate. QRICH1 suppresses aberrant T cell activation by binding to and negatively regulating CARD11–NF-κB signaling, thus modulating immunity. Disease-associated variants lead to neurodevelopmental syndromes, and recent work demonstrates a suppressive role in pediatric leukemia. No approved drugs directly target QRICH1, and its exact physiological and molecular roles are the subject of ongoing research.
- Other names
- QRICH1Glutamine-rich protein 1FLJ20259VERBRASAB-DIPTranscriptional regulator QRICH1
02
Mechanism of action
Drugs targeting QRICH1 would likely act by modulating its transcriptional activity, CARD domain interactions, or ISR-related pathways, chiefly affecting UPR and NF-κB signaling
03
Biological functions
Transcriptional regulation in response to cellular stress (particularly ER stress)Regulation of protein homeostasis and unfolded protein response (UPR)Negative regulation of CARD11–NF-κB signaling in T cellsApoptosisInflammationImmune response
04
Disease associations
Neurodevelopmental disorders (e.g., Ververi-Brady syndrome)Pediatric T-cell acute lymphoblastic leukemia suppressionPotential roles in autoimmune diseases and inflammatory diseases (based on regulation of NF-κB and apoptosis)Possibly associated with ASD (autism spectrum disorder)Hematological cancers (based on T cell function modulation)
05
Safety considerations
Therapeutic modulation may risk immune dysregulationAbnormal apoptosisExacerbation of ER stress–linked disordersNo direct drug safety experience is available
06
Interacting drugs
None reported in peer-reviewed literature or clinical databases as of 2025
07
Biomarkers
QRICH1 mutations and expression levels have been proposed as biomarkers for Ververi-Brady syndrome and for terminal UPR-mediated proteotoxicity, but are not yet widely validated in clinical practice
Beyond the preview
Go deeper on Glutamine-rich protein 1 (QRICH1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Glutamine-rich protein 1 (QRICH1).